Martin Crowley & Arturo Ferreira
September 20, 2023
Premium // Sponsorship // Consulting
We’ve got some good news for you today—just about every tech firm on the planet is investing in AI x healthcare/life sciences research.
_________________________________________________________________
Today:
🧬 Zuckerberg attempts to cure all diseases with AI
Read Time: 4 minutes
Our Report: The Chan Zuckerberg Initiative, is set to develop an AI-driven computing system specifically designed for life sciences research—to delve deeper into the study of human cells and diseases using AI.
🔑 Key Points:
The project will leverage openly accessible AI models to carry out research, accelerating the push toward the venture's ambitious goal of curing, preventing, and managing all diseases.
AI's integration in life sciences has been evident for years, with platforms like Google DeepMind's AlphaFold predicting protein structures and producing incredibly accurate predictions for cancer, alzheimers, and other diseases.
The AI system will be trained using datasets from the CZ Cell x Gene software tool, the Chan Zuckerberg Biohub Network, the Chan Zuckerberg Institute for Advanced Biological Imaging, and other public data sources.
Zuckerberg highlighted the advantages of crowdsourcing the development of the model, including making the project open-source and available to a wider variety of users.
🤨 Why you should care: With major investments such as this, we can expect accelerated advancements in medical science, potentially leading to groundbreaking treatments and solutions for various diseases.
In Partnership with Masterworks
Over the last 20 years, record prices achieved for Banksy’s art have grown at an astounding 63% compound annual rate. Impressive to say the least. But even more impressive? It's not just the ultra-wealthy benefiting from this phenomenal growth…
Masterworks enables its 820,000+ users to access investments in multi-million dollar artworks by artists like Banksy, Basquiat, and Picasso for just a fraction of the cost of an entire piece. When Masterworks sells a painting – like the 16 it’s already sold – investors receive their portion of the net proceeds.
Every single one of Masterworks’ sales has generated returns for investors, with 3 recent sales, realizing net annualized returns of 17.6%, 21.5% and 35%.
All of their offerings are limited, and shares can sell out in just minutes, but AI Tool Report readers can stay ahead:
PromptPerfect is Prompt Engineering at its finest: Design. Optimize. Deploy. Instantly.
1PhotoAI generates countless headshots from 1 selfie using AI
Debunkd helps you fact-check any ChatGPT result
Hayt lets you chat with your documents on Mac
TopDesign is an AI design agency with a spin
✅ PASTOR Framework
copy & paste ⬇️
"Using the 'PASTOR' framework, write a marketing campaign outline that addresses the pain points of [ideal customer persona] and presents our [product/service] as the solution. Identify the [problem] they are facing, amplify the consequences of not solving it, tell a [story] related to the problem, include [testimonials] from happy customers, present our [offer], and request a response.”
🎨 Telephoto Lenses
copy & paste ⬇️
“Zoomed in portraits,” “Isolated subjects,” “Compressed landscapes,” “Long-distance shots,” “Bokeh background.”
Intel introduced a new chip (Meteor Lake), set for December release, that allows generative AI chatbots to operate on laptops without needing cloud data centers (imagine always having an AI at your fingertips).
This advancement will enhance data privacy and increase AI accessibility for businesses and individuals as users no longer have to rely on online access to utilize AI. Another massive step forward for Enterprise use cases.
Elon Musk's company Neuralink has received FDA approval and clearance from an independent review board to start human trials for its brain-computer interface, "the Link".
This technology aims to allow users to control devices with their thoughts, and has the potential to bridge neurological gaps for the blind, deaf, motor impaired & more.
Google DeepMind has developed an AI—AlphaMissense—that predicts whether genetic mutations are harmful or benign by focusing on missense mutations in DNA.
By analyzing 71 million mutations, it determined that 57% were likely harmless and 32% harmful—with the model outperforming current predictive tools, offering faster and more precise insights into mutation-driven diseases, and expediting research and diagnosis of rare disorders.
The AI Tool Report just became the fastest-growing AI newsletter in the world, with 350,000+ readers working at companies like Apple, Meta, Google, Microsoft, and many more. We are now taking limited bookings for products that are a good fit. Book your ad spot by clicking here
📚 Nolej supercharges learning in the classroom with AI education tools
📈 Google announces new Bard features as traffic lags ChatGPT
🎈OpenAI introduces red-teaming network to develop safer AI
🤝 UN utilizes AI to track progress toward global goals
🍟 New SambaNova chip handles 5 trillion parameters
What's Miruna's tagline?Today's Top Trending Tool... |
Hit reply and let us know what you want more of!
Until next time, Martin & Arturo.
What'd you think of this edition? |